PEAK6 Group’s Charles River Laboratories CRL Stock Holding History

PEAK6 Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$898K	Buy	+8,000	New	+$865K	﹤0.01%	2055
2018 Q1	–	Sell	-7,500	Closed	-$821K	–	4405
2017 Q4	$821K	Buy	+7,500	New	+$816K	﹤0.01%	2075
2017 Q2	–	Sell	-200	Closed	-$18K	–	4608
2017 Q1	$18K	Buy	200 +100	+100%	+$8.49K	﹤0.01%	4073
2016 Q4	$8K	Sell	100 -74,300	-100%	-$5.64M	﹤0.01%	4539
2016 Q3	$6.2M	Buy	+74,400	New	+$6.24M	0.05%	571
2015 Q2	–	Sell	-10,800	Closed	-$856K	–	5061
2015 Q1	$856K	Buy	10,800 +5,300	+96%	+$391K	0.01%	2038
2014 Q4	$350K	Buy	+5,500	New	+$345K	﹤0.01%	2879
2014 Q3	–	Sell	-5,500	Closed	-$294K	–	4735
2014 Q2	$294K	Sell	5,500 -2,500	-31%	-$137K	﹤0.01%	2836
2014 Q1	$482K	Buy	+8,000	New	+$466K	﹤0.01%	2586

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Group's CRL Position: Q2 2018 in Review

PEAK6 Group reduced its Charles River Laboratories (CRL) stake by 64% in Q2 2018, selling an estimated $875K and leaving 4,469 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #2590.

PEAK6 Group first reported a position in CRL in Q4 2013 and has held it in 13 quarters since. The position peaked at $1.81M in Q1 2014. 348 funds tracked by Wall St. Rank hold CRL as of Q2 2018.

PEAK6 Group held 4,469 shares of Charles River Laboratories worth $502K as of Q2 2018.
PEAK6 Group sold 8,098 Charles River Laboratories shares in Q2 2018, an estimated $875K.
Charles River Laboratories made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #2590 holding.
PEAK6 Group first reported a position in Charles River Laboratories in Q4 2013 and has held it in 13 quarters since.
PEAK6 Group's Charles River Laboratories position peaked at $1.81M in Q1 2014.
348 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.